GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovoRx Inc (NAS:RNXT) » Definitions » Price-to-Owner-Earnings

RenovoRx (RenovoRx) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is RenovoRx Price-to-Owner-Earnings?

As of today (2024-06-19), RenovoRx's share price is $1.37. RenovoRx does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for RenovoRx's Price-to-Owner-Earnings or its related term are showing as below:


RNXT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.725
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), RenovoRx's share price is $1.37. RenovoRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.72. Therefore, RenovoRx's PE Ratio for today is At Loss.

As of today (2024-06-19), RenovoRx's share price is $1.37. RenovoRx's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.97. Therefore, RenovoRx's PE Ratio without NRI for today is At Loss.


RenovoRx Price-to-Owner-Earnings Historical Data

The historical data trend for RenovoRx's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovoRx Price-to-Owner-Earnings Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

RenovoRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RenovoRx's Price-to-Owner-Earnings

For the Biotechnology subindustry, RenovoRx's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where RenovoRx's Price-to-Owner-Earnings falls into.



RenovoRx Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

RenovoRx's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.37/-0.94
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovoRx  (NAS:RNXT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


RenovoRx Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of RenovoRx's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovoRx (RenovoRx) Business Description

Traded in Other Exchanges
N/A
Address
4546 El Camino Real, Suite B1, Los Altos, CA, USA, 94022
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 pancreatic cancer clinical trial for its lead product candidate RenovoGem.
Executives
Angela Nelms officer: Chief Operating Officer C/O RENOVORX, INC., 4546 EL CAMINO REAL, SUITE B1, LOS ALTOS CA 94022
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
James M Ahlers officer: Chief Financial Officer 2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Ramtin Agah director, officer: Chief Medical Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Shaun Bagai director, officer: Chief Executive Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Bank Of The West 10 percent owner PO BOX 60078, LOS ANGELES CA 90060
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Laurence Marton director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kirsten Angela Macfarlane director 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Christopher John Lehman officer: Chief Financial Officer 65 OAK RIDGE ROAD, BERKELEY, BERKELEY CA 94705
Paul Manners officer: Chief Financial Officer 4546 EL CAMINO REAL, SUITE 223, LOS ALTOS CA 94022
Kamran Najmabadi 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303
Najmabadi Family Trust Dated April 22, 2021 10 percent owner 3114 DAVID AVE., PALO ALTO CA 94303

RenovoRx (RenovoRx) Headlines